Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) Debt Ratio (2016 - 2025)

Heron Therapeutics' Debt Ratio history spans 5 years, with the latest figure at 0.42 for Q4 2025.

  • For Q4 2025, Debt Ratio rose 292.85% year-over-year to 0.42; the TTM value through Dec 2025 reached 0.42, up 292.85%, while the annual FY2025 figure was 0.42, 292.85% up from the prior year.
  • Debt Ratio reached 0.42 in Q4 2025 per HRTX's latest filing, down from 0.43 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.43 in Q3 2025 to a low of 0.1 in Q3 2023.
  • Average Debt Ratio over 3 years is 0.18, with a median of 0.11 recorded in 2024.
  • The largest YoY upside for Debt Ratio was 292.85% in 2025 against a maximum downside of 4.68% in 2025.
  • A 3-year view of Debt Ratio shows it stood at 0.11 in 2023, then dropped by 1.56% to 0.11 in 2024, then surged by 292.85% to 0.42 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Debt Ratio are 0.42 (Q4 2025), 0.43 (Q3 2025), and 0.11 (Q1 2025).